WO2011088215A3 - Notch1 binding agents and methods of use thereof - Google Patents

Notch1 binding agents and methods of use thereof Download PDF

Info

Publication number
WO2011088215A3
WO2011088215A3 PCT/US2011/021135 US2011021135W WO2011088215A3 WO 2011088215 A3 WO2011088215 A3 WO 2011088215A3 US 2011021135 W US2011021135 W US 2011021135W WO 2011088215 A3 WO2011088215 A3 WO 2011088215A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
present
notch1
agents
treating
Prior art date
Application number
PCT/US2011/021135
Other languages
French (fr)
Other versions
WO2011088215A2 (en
Inventor
Edward Thein Htun Van Der Horst
Original Assignee
Oncomed Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticals, Inc. filed Critical Oncomed Pharmaceuticals, Inc.
Priority to MX2012008085A priority Critical patent/MX2012008085A/en
Priority to CN201180009457.3A priority patent/CN102958534B/en
Priority to EP11733378.1A priority patent/EP2523682B1/en
Priority to AU2011205316A priority patent/AU2011205316B2/en
Priority to ES11733378.1T priority patent/ES2561102T3/en
Publication of WO2011088215A2 publication Critical patent/WO2011088215A2/en
Publication of WO2011088215A3 publication Critical patent/WO2011088215A3/en
Priority to HK13108710.7A priority patent/HK1181316A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.
PCT/US2011/021135 2010-01-13 2011-01-13 Notch1 binding agents and methods of use thereof WO2011088215A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2012008085A MX2012008085A (en) 2010-01-13 2011-01-13 Notch1 binding agents and methods of use thereof.
CN201180009457.3A CN102958534B (en) 2010-01-13 2011-01-13 Notch1 binding agents and methods of use thereof
EP11733378.1A EP2523682B1 (en) 2010-01-13 2011-01-13 Notch1 binding agents and methods of use thereof
AU2011205316A AU2011205316B2 (en) 2010-01-13 2011-01-13 Notch1 binding agents and methods of use thereof
ES11733378.1T ES2561102T3 (en) 2010-01-13 2011-01-13 Binding agents to Notch1 and procedures for their use
HK13108710.7A HK1181316A1 (en) 2010-01-13 2013-07-25 Notch1 binding agents and methods of use thereof notch1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29476210P 2010-01-13 2010-01-13
US61/294,762 2010-01-13
US41065110P 2010-11-05 2010-11-05
US61/410,651 2010-11-05

Publications (2)

Publication Number Publication Date
WO2011088215A2 WO2011088215A2 (en) 2011-07-21
WO2011088215A3 true WO2011088215A3 (en) 2011-09-29

Family

ID=44304970

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/021135 WO2011088215A2 (en) 2010-01-13 2011-01-13 Notch1 binding agents and methods of use thereof

Country Status (8)

Country Link
US (1) US8834875B2 (en)
EP (1) EP2523682B1 (en)
CN (1) CN102958534B (en)
AU (1) AU2011205316B2 (en)
ES (1) ES2561102T3 (en)
HK (1) HK1181316A1 (en)
MX (1) MX2012008085A (en)
WO (1) WO2011088215A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539403A (en) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosing and treating cancer
EP2125887A4 (en) 2007-01-24 2010-11-10 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
SG192467A1 (en) 2008-07-08 2013-08-30 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2010146550A1 (en) 2009-06-18 2010-12-23 Pfizer Inc. Anti notch-1 antibodies
BR112013015122A2 (en) 2010-12-15 2017-05-30 Wyeth Llc anti-notch1 antibodies
WO2012080891A1 (en) * 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies
US9352039B2 (en) 2012-02-09 2016-05-31 The Regents Of The University Of Michigan Method of reducing the number of EMT and MET type breast cancer stem cells
CA2885659A1 (en) * 2012-09-21 2014-03-27 Oncomed Pharmaceuticals, Inc. Methods of treating hematological malignancies with notch1 antibodies
EP2934586A4 (en) * 2012-12-21 2016-05-25 Univ California Tspan 33 is a candidate for antibody targeted therapy for the treatment of b cell hodgkin lymphomas
WO2014172653A2 (en) * 2013-04-19 2014-10-23 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
CN103820498B (en) * 2014-01-29 2016-08-17 中国人民解放军第四军医大学 A kind of Lentiviral built based on Notch signal intracellular territory NICD1 and application thereof
CA2952315A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
EP3212233B1 (en) * 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN105585636B (en) * 2015-11-24 2020-03-03 南方医科大学 Human NOTCH1NICD protein Ser2162 site phosphorylation antibody and preparation method and application thereof
CN106591229A (en) * 2017-01-20 2017-04-26 南京千年健干细胞基因工程有限公司 Application of miR-34a and target gene NOTCH1 to preparation of mesenchymal stem cell based glioma targeting carrier
WO2019099852A1 (en) * 2017-11-17 2019-05-23 University Of Massachusetts Humanized 2c7 monoclonal antibody directed against a neisseria gonorrhoeae lipooligosaccharide (los) epitope, for human use
EP3877399A4 (en) * 2018-11-06 2022-10-19 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080588A (en) * 1995-05-18 2000-06-27 The Regents Of The University Of Michigan Therapeutic methods for benzodiazepine derivatives
US20040229301A1 (en) * 2003-04-22 2004-11-18 Baiyang Wang Tissue factor antibodies and uses thereof
US20050142635A1 (en) * 1991-04-25 2005-06-30 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6 receptor
US20090028856A1 (en) * 2007-07-16 2009-01-29 Genentech, Inc. Anti-CD79B Antibodies and Immunoconjugates and Methods of Use
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
US7632926B2 (en) * 2006-04-01 2009-12-15 Galaxy Biotech, Llc Humanized monoclonal antibodies to hepatocyte growth factor

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20050112121A1 (en) 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
DE4425115A1 (en) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Method for modifying the stability of antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69621940T2 (en) 1995-08-18 2003-01-16 Morphosys Ag PROTEIN - / (POLY) PEPTIDE LIBRARIES
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
CA2250394A1 (en) 1996-03-30 1997-10-09 Boehringer Mannheim Gmbh Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors
EP0921818A4 (en) 1996-05-31 2002-09-25 Nat American Red Cross Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
FR2751986B1 (en) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med GENE INVOLVED IN CADASIL, DIAGNOSTIC METHOD AND THERAPEUTIC APPLICATION
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
WO1998057621A1 (en) 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction
US6692919B1 (en) 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
EP1117778A2 (en) 1998-10-02 2001-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein
EP1127487B1 (en) 1998-11-05 2006-10-11 Japan Science and Technology Agency Adult t cell leukemia model animal
US20030003572A1 (en) 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
EP1133565B1 (en) 1999-07-02 2010-09-22 MorphoSys AG Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
DE10031380A1 (en) 2000-06-28 2002-01-10 Merck Patent Gmbh Process for the transfer of alkylidene groups to organic compounds
US20080194022A1 (en) 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US20050089518A1 (en) 2001-12-07 2005-04-28 Clarke Michael F. Prospective identification and characterization of breast cancer stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6930222B2 (en) 2000-08-22 2005-08-16 The Scripps Research Institute In vivo animal model of human leukemia
WO2002018544A2 (en) 2000-08-31 2002-03-07 Loyola University Chicago Method and reagents for treatment of skin disorders by modulating the notch pathway
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
DE60143544D1 (en) 2000-12-12 2011-01-05 Medimmune Llc MOLECULES WITH LONGER MID-TERM, COMPOSITIONS AND THEIR USE
US7356224B2 (en) 2001-07-03 2008-04-08 Brown University Research Foundation Method and apparatus for detecting multiple optical wave lengths
AU2002339157A1 (en) 2001-11-14 2003-05-26 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
GB0201674D0 (en) 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
EP2365004B1 (en) 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1578367A4 (en) 2002-11-01 2012-05-02 Genentech Inc Compositions and methods for the treatment of immune related diseases
US20060122110A1 (en) 2002-12-06 2006-06-08 Zhi-Cheng Xiao Nogo, caspr, f3 nb-3 useful in the treatment of injury and disease to the central nervous system
EP1608255A4 (en) 2003-04-01 2008-06-25 Univ Johns Hopkins Med Breast endothelial cell expression patterns
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
JP2007512348A (en) 2003-11-26 2007-05-17 ヘルス　リサーチ　インコーポレイテッド Use of Notch pathway interference agents for the treatment of plasma cells
AU2005209909B8 (en) 2004-02-03 2009-01-15 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
EP1730531B1 (en) 2004-03-24 2014-01-15 Technion Research and Development Foundation, Limited Electrode
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
WO2006024497A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
GB0421838D0 (en) 2004-09-30 2004-11-03 Congenia S R L Cancer markers
JP2008519829A (en) 2004-11-10 2008-06-12 ヒュブレヒト ラボラトリウム Treatment of intestinal adenoma and / or adenocarcinoma by inhibition of Notch pathway activation
CA2998412C (en) 2004-11-12 2024-01-02 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
JP2008535494A (en) 2005-04-07 2008-09-04 サグレシュ ディスカバリー， インコーポレイテッド Cancer-related gene (PRLR)
EP1945754B1 (en) 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
PL1962895T3 (en) 2005-12-16 2013-06-28 Regeneron Pharma THERAPEUTIC USE OF A Dll4 ANTAGONIST AND A VEGF INHIBITOR FOR INHIBITING TUMOR GROWTH
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
TW200817435A (en) 2006-06-06 2008-04-16 Genentech Inc Compositions and methods for modulating vascular development
TW200815467A (en) 2006-06-06 2008-04-01 Genentech Inc Anti-DLL4 antibodies and methods using same
JP2009539403A (en) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosing and treating cancer
EA018260B1 (en) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Antibodies to human delta-like ligand 4 (dll4) and use thereof
RU2461569C2 (en) 2006-10-19 2012-09-20 Дженентек, Инк. Agonist notch3 antibodies and application thereof for treating notch3-associated diseases
PE20080891A1 (en) 2006-10-19 2008-08-25 Genentech Inc ANTI-NOTCH3 ANTIBODIES AND COMPOSITIONS THAT INCLUDE THEM
US7700113B2 (en) 2006-10-19 2010-04-20 Maine Medical Research Institute, A Division Of Maine Medical Center Inhibiting breast cancer cell growth by administering an intracellular domain of NOTCH2
NO347649B1 (en) 2006-12-14 2024-02-12 Regeneron Pharma Human antibody or antibody fragment that specifically binds human delta-like ligand 4 (hDII4), nucleic acid molecule that codes for such and vector and host-vector systems, as well as method for production, composition and use.
KR101568049B1 (en) 2006-12-18 2015-11-11 제넨테크, 인크. -3 3- antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
WO2008079326A2 (en) 2006-12-20 2008-07-03 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2125887A4 (en) 2007-01-24 2010-11-10 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
US20100119526A1 (en) 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
JP2010520280A (en) 2007-03-05 2010-06-10 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Negative genetic control of cancer cell regeneration with synergy with Notch or Num specific immunotherapy
PE20090321A1 (en) 2007-06-04 2009-04-20 Genentech Inc ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION
AU2008289462B2 (en) 2007-08-23 2014-01-23 The Trustees Of Columbia University In The City Of New York Compositions of humanized notch fusion proteins and methods of treatment
US8377886B2 (en) 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
SG192467A1 (en) 2008-07-08 2013-08-30 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142635A1 (en) * 1991-04-25 2005-06-30 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6 receptor
US6080588A (en) * 1995-05-18 2000-06-27 The Regents Of The University Of Michigan Therapeutic methods for benzodiazepine derivatives
US20040229301A1 (en) * 2003-04-22 2004-11-18 Baiyang Wang Tissue factor antibodies and uses thereof
US7632926B2 (en) * 2006-04-01 2009-12-15 Galaxy Biotech, Llc Humanized monoclonal antibodies to hepatocyte growth factor
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
US20090028856A1 (en) * 2007-07-16 2009-01-29 Genentech, Inc. Anti-CD79B Antibodies and Immunoconjugates and Methods of Use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE SWISS-PROT [online] 31 October 2006 (2006-10-31), "Anti-MOG Z12 variable gamma 2a.", retrieved from http://www.ncbi.nlm.nih.gov/protein/Q8VDC9 Database accession no. 08VDC9 *
DATABASE SWISS-PROT [online] 4 November 2008 (2008-11-04), "Ig lambda-1 chain V regions MOPC 104E/RPC20/J558/S104.", retrieved from http://www.ncbi.nlm.nih.gov/proteiN126540?sat=OL106&satkey=9150932 Database accession no. P01724. *
See also references of EP2523682A4 *

Also Published As

Publication number Publication date
CN102958534B (en) 2014-11-05
WO2011088215A2 (en) 2011-07-21
EP2523682B1 (en) 2015-12-16
ES2561102T3 (en) 2016-02-24
AU2011205316A1 (en) 2012-08-02
US8834875B2 (en) 2014-09-16
US20120213786A1 (en) 2012-08-23
HK1181316A1 (en) 2013-11-08
EP2523682A2 (en) 2012-11-21
AU2011205316B2 (en) 2015-05-28
CN102958534A (en) 2013-03-06
MX2012008085A (en) 2012-09-12
EP2523682A4 (en) 2013-05-29

Similar Documents

Publication Publication Date Title
WO2011088215A3 (en) Notch1 binding agents and methods of use thereof
MY155603A (en) Notch-binding agents and antagonists and methods of use thereof
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
MX2018010331A (en) Vegf/dll4 binding agents and uses thereof.
WO2011063237A3 (en) Jagged-binding agents and uses thereof
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
WO2011119979A3 (en) Antibodies to muc16 and methods of use thereof
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
WO2008091641A3 (en) Compositions and methods for diagnosing and treating cancer
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
EA033400B1 (en) Anti-cd3 antibody and use thereof
WO2013071068A3 (en) Treatment of hematologic malignancies with an anti-cxcr4 antibody
MX2009013656A (en) Anti-cd20 therapeutic compositions and methods.
UA94452C2 (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2011160119A3 (en) Anti-gd2 antibodies
EP4406550A3 (en) Antibodies to cd40 with enhanced agonist activity
EP2175879A4 (en) Treatment of prion protein related diseases
PH12020551447A1 (en) Antibodies
WO2008142303A3 (en) Use of an anti-cxcr4 antibody for treating cancer
MX2009003039A (en) Use of an anti-cd151 antibody in the treatment of cancer.
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer
WO2010066914A3 (en) Remedies for pemphigus containing anti fas ligand antibodies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180009457.3

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2011205316

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/008085

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011733378

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011205316

Country of ref document: AU

Date of ref document: 20110113

Kind code of ref document: A